Answers are grounded in this paper and cite their sources.
Meta-analysis reports reduced transfusion burden in β-thalassemia patients receiving luspatercept, indicating notable safety with low adverse events.
Background β-thalassaemia is a genetic blood disorder marked by ineffective erythropoiesis and chronic anaemia, often requiring lifelong red blood cell (RBC) transfusions. Luspatercept, an erythroid maturation agent, has emerged as a potential therapy to reduce the transfusion burden in affected patients. This study aims to assess the outcomes with luspatercept in patients with β-thalassemia. Methods Following PRISMA guidelines, a comprehensive search of PubMed, Cochrane, Embase, Google Scholar, and ClinicalTrials.gov (inception to May 2025) was conducted using MeSH terms for “ β-thalassaemia” and ”luspatercept.” After screening and excluding review articles, meta-analyses, and studies without a patient population of interest, four studies reporting the outcomes of luspatercept in patients with β-thalassemiawere selected for inclusion from a total of 587 references. Some characteristics were described systematically. Pooled estimates were calculated using a random-effects model, and heterogeneity was assessed using the I² statistic. Results A total of 447 patients from three Phase II and one Phase III trials were included for analysis and review. The median age was 38,25 years (range, 18-66), 56% (n = 249/447) were females. The pooled rate for transfusion independence was 36% (95% CI 0.13-0.69, I2 90.4%, p < 0.0001). The pooled rates for reduction in transfusion burden by >33% and >50% were 58% (95% CI 0.33-0.79, I2 92%%, p < 0.0001) and 40% (95% CI 0.25-0.58, I2 83.3%, p + 0.0004), respectively. The pooled rate for mean increase in serum haemoglobin by >1 g/dL was 69% (95% CI 0.53-0.81, I2 66.9%, p = 0.0488). The pooled rate for grade 3 or above adverse events was 21% (95% CI 0.09-0.41, I2 92.9%%, p < 0.0001). The pooled rates for pyrexia, headache, and nausea were 14% (95% CI 0.07-0.25, I2 76.7%, p = 0.0137), 32% (95% CI 0.28-0.37, I2 0.0 %, p = 0.4771), and 10% (95% CI 0.06-0.17, I2 54.2%, p = 0.1127), respectively. The pooled rate for arthralgias, asthenia, and injection site adverse events were 23% (95% CI 0.19-0.28, I2 9.9%, p = 0.3435), 12% (95% CI 0.09-0.16, I2 0.0%, p = 0.8251), and 8% (95% CI 0.0.05-0.13, I2 56.4%, p = 0.0758), respectively. Conclusion Luspatercept significantly reduces the transfusion burden in patients with β-thalassemia and demonstrates a favourable safety profile. This study supports the use of luspatercept as an effective and well-tolerated therapeutic option for β-thalassemia while highlighting the need for continued research to consolidate these findings.
No takes yet. Share an insight, caveat, or question.
Babiker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: